NZ613029B - Testosterone formulations - Google Patents
Testosterone formulations Download PDFInfo
- Publication number
- NZ613029B NZ613029B NZ613029A NZ61302912A NZ613029B NZ 613029 B NZ613029 B NZ 613029B NZ 613029 A NZ613029 A NZ 613029A NZ 61302912 A NZ61302912 A NZ 61302912A NZ 613029 B NZ613029 B NZ 613029B
- Authority
- NZ
- New Zealand
- Prior art keywords
- formulation
- testosterone
- amount
- transdermal
- present
- Prior art date
Links
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 title claims abstract description 534
- 239000000203 mixture Substances 0.000 title claims abstract description 251
- 229960003604 Testosterone Drugs 0.000 title claims abstract description 250
- 238000009472 formulation Methods 0.000 claims abstract description 198
- MTHSVFCYNBDYFN-UHFFFAOYSA-N Diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims abstract description 39
- 150000002191 fatty alcohols Chemical class 0.000 claims abstract description 23
- 150000002194 fatty esters Chemical class 0.000 claims abstract description 23
- 150000001346 alkyl aryl ethers Chemical class 0.000 claims abstract description 19
- 125000004432 carbon atoms Chemical group C* 0.000 claims abstract description 9
- 239000002253 acid Substances 0.000 claims abstract description 4
- 125000003158 alcohol group Chemical group 0.000 claims abstract description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 4
- 239000000194 fatty acid Substances 0.000 claims abstract description 4
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 4
- 239000003961 penetration enhancing agent Substances 0.000 claims abstract 3
- 239000000499 gel Substances 0.000 claims description 85
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 76
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 74
- 210000003491 Skin Anatomy 0.000 claims description 46
- 201000010099 disease Diseases 0.000 claims description 44
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 37
- 229920001888 polyacrylic acid Polymers 0.000 claims description 37
- 229960001631 Carbomer Drugs 0.000 claims description 33
- 238000004519 manufacturing process Methods 0.000 claims description 28
- 241000124008 Mammalia Species 0.000 claims description 27
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical group OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 27
- XXJWXESWEXIICW-UHFFFAOYSA-N 2-(2-Ethoxyethoxy)ethanol Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 25
- 239000012528 membrane Substances 0.000 claims description 24
- 239000003795 chemical substances by application Substances 0.000 claims description 23
- 230000002354 daily Effects 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 claims description 22
- 229960001484 Edetic Acid Drugs 0.000 claims description 19
- 210000001015 Abdomen Anatomy 0.000 claims description 18
- 239000003349 gelling agent Substances 0.000 claims description 17
- 230000003472 neutralizing Effects 0.000 claims description 15
- 239000002738 chelating agent Substances 0.000 claims description 13
- 239000002904 solvent Substances 0.000 claims description 13
- -1 liposomal system Substances 0.000 claims description 8
- 206010058359 Hypogonadism Diseases 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propanol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- SBASXUCJHJRPEV-UHFFFAOYSA-N 2-(2-Methoxyethoxy)ethanol Chemical compound COCCOCCO SBASXUCJHJRPEV-UHFFFAOYSA-N 0.000 claims description 2
- 229940046011 Buccal Tablet Drugs 0.000 claims description 2
- 229940098466 Sublingual Tablet Drugs 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 239000006189 buccal tablet Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004922 lacquer Substances 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000006190 sub-lingual tablet Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 230000003442 weekly Effects 0.000 claims description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L disodium;2-[2-[carboxylatomethyl(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetate Chemical group [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 4
- 229960004063 Propylene glycol Drugs 0.000 description 32
- 230000035515 penetration Effects 0.000 description 31
- 230000035492 administration Effects 0.000 description 29
- 210000004379 Membranes Anatomy 0.000 description 23
- 229960004418 Trolamine Drugs 0.000 description 23
- 229940079593 drugs Drugs 0.000 description 21
- 230000035533 AUC Effects 0.000 description 20
- 229940062331 Androgel Drugs 0.000 description 19
- 150000004668 long chain fatty acids Chemical class 0.000 description 19
- 229910052799 carbon Inorganic materials 0.000 description 17
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 16
- 230000004907 flux Effects 0.000 description 16
- 230000001955 cumulated Effects 0.000 description 15
- 230000002708 enhancing Effects 0.000 description 14
- 238000000338 in vitro Methods 0.000 description 14
- 230000001965 increased Effects 0.000 description 14
- 230000000275 pharmacokinetic Effects 0.000 description 14
- 210000000689 upper leg Anatomy 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 10
- 230000036823 Plasma Levels Effects 0.000 description 9
- 239000003098 androgen Substances 0.000 description 9
- 229960003473 androstanolone Drugs 0.000 description 9
- 210000002381 Plasma Anatomy 0.000 description 8
- 102000034956 Sex Hormone-Binding Globulin Human genes 0.000 description 7
- 108010089417 Sex Hormone-Binding Globulin Proteins 0.000 description 7
- 230000037335 skin penetration Effects 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 210000002966 Serum Anatomy 0.000 description 5
- 210000001550 Testis Anatomy 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 210000004027 cells Anatomy 0.000 description 5
- 230000003247 decreasing Effects 0.000 description 5
- 238000009792 diffusion process Methods 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 238000011068 load Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 5
- 208000001132 Osteoporosis Diseases 0.000 description 4
- 230000037165 Serum Concentration Effects 0.000 description 4
- 210000002832 Shoulder Anatomy 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000004059 degradation Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000001105 regulatory Effects 0.000 description 4
- 230000001568 sexual Effects 0.000 description 4
- 230000001225 therapeutic Effects 0.000 description 4
- 229940030486 ANDROGENS Drugs 0.000 description 3
- 210000004369 Blood Anatomy 0.000 description 3
- 229940085237 Carbomer-980 Drugs 0.000 description 3
- 206010057671 Female sexual dysfunction Diseases 0.000 description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 3
- 210000004400 Mucous Membrane Anatomy 0.000 description 3
- 210000003205 Muscles Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000000875 corresponding Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 231100000486 side effect Toxicity 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000037317 transdermal delivery Effects 0.000 description 3
- 229940029612 triethanolamine Drugs 0.000 description 3
- 230000036642 wellbeing Effects 0.000 description 3
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- CWSZBVAUYPTXTG-UHFFFAOYSA-N 5-[6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[4-hydroxy-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OCCO)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 CWSZBVAUYPTXTG-UHFFFAOYSA-N 0.000 description 2
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 description 2
- 206010002261 Androgen deficiency Diseases 0.000 description 2
- 210000000988 Bone and Bones Anatomy 0.000 description 2
- 230000035839 C max Effects 0.000 description 2
- UAOMVDZJSHZZME-UHFFFAOYSA-N Diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 2
- 229920000896 Ethulose Polymers 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 239000001859 Ethyl hydroxyethyl cellulose Substances 0.000 description 2
- 229940088597 Hormone Drugs 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 230000036740 Metabolism Effects 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 description 2
- 210000003635 Pituitary Gland Anatomy 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010052649 Primary hypogonadism Diseases 0.000 description 2
- 229940035504 Tromethamine Drugs 0.000 description 2
- 238000010811 Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry Methods 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000001919 adrenal Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000001335 aliphatic alkanes Chemical group 0.000 description 2
- 229920002892 amber Polymers 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-M caprate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 2
- 230000001684 chronic Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 238000009164 estrogen replacement therapy Methods 0.000 description 2
- 229960004756 ethanol Drugs 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 235000019326 ethyl hydroxyethyl cellulose Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000035786 metabolism Effects 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 230000036231 pharmacokinetics Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035946 sexual desire Effects 0.000 description 2
- 201000007196 sexual disease Diseases 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 150000003515 testosterones Chemical class 0.000 description 2
- 210000001519 tissues Anatomy 0.000 description 2
- 231100000730 tolerability Toxicity 0.000 description 2
- 230000000699 topical Effects 0.000 description 2
- 229960000281 trometamol Drugs 0.000 description 2
- JOLQKTGDSGKSKJ-UHFFFAOYSA-N 1-ethoxypropan-2-ol Chemical compound CCOCC(C)O JOLQKTGDSGKSKJ-UHFFFAOYSA-N 0.000 description 1
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-Methyl-2,4-pentanediol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 1
- KWVPFECTOKLOBL-KTKRTIGZSA-N 2-[(Z)-octadec-9-enoxy]ethanol Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCO KWVPFECTOKLOBL-KTKRTIGZSA-N 0.000 description 1
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- IQMTVJBLQXREOP-UHFFFAOYSA-N 2H-phenanthren-1-one Chemical compound C1=CC2=CC=CC=C2C2=C1C(=O)CC=C2 IQMTVJBLQXREOP-UHFFFAOYSA-N 0.000 description 1
- JMFLYAQVWMIMKC-UHFFFAOYSA-N 3-(2-aminoethylamino)propane-1,1,1,3-tetrol Chemical compound NCCNC(O)CC(O)(O)O JMFLYAQVWMIMKC-UHFFFAOYSA-N 0.000 description 1
- 210000004100 Adrenal Glands Anatomy 0.000 description 1
- 206010001367 Adrenal insufficiency Diseases 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 210000001099 Axilla Anatomy 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- 229950007169 Buciclate Drugs 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 229940043234 Carbomer-940 Drugs 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 208000001590 Congenital Abnormality Diseases 0.000 description 1
- 206010011652 Cushing's syndrome Diseases 0.000 description 1
- 240000005497 Cyamopsis tetragonoloba Species 0.000 description 1
- FKUPPRZPSYCDRS-UHFFFAOYSA-N Cyclopentadecanolide Chemical compound O=C1CCCCCCCCCCCCCCO1 FKUPPRZPSYCDRS-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N Cypionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- 206010011953 Decreased activity Diseases 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 210000004207 Dermis Anatomy 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N Diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 210000002615 Epidermis Anatomy 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 229940011871 Estrogens Drugs 0.000 description 1
- YLRFCQOZQXIBAB-RBZZARIASA-N Fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
- 229960001751 Fluoxymesterone Drugs 0.000 description 1
- 210000002683 Foot Anatomy 0.000 description 1
- 229940110436 Fortesta Drugs 0.000 description 1
- 206010017885 Gastrooesophageal reflux disease Diseases 0.000 description 1
- 229940065521 Glucocorticoid inhalants for obstructive airway disease Drugs 0.000 description 1
- 229940015001 Glycerin Drugs 0.000 description 1
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 1
- 108010084340 Gonadotropin-Releasing Hormone Proteins 0.000 description 1
- 206010018872 Haemochromatosis Diseases 0.000 description 1
- 210000004247 Hand Anatomy 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 208000000509 Infertility Diseases 0.000 description 1
- 206010022114 Injury Diseases 0.000 description 1
- AXISYYRBXTVTFY-UHFFFAOYSA-N Isopropyl myristate Chemical compound CCCCCCCCCCCCCC(=O)OC(C)C AXISYYRBXTVTFY-UHFFFAOYSA-N 0.000 description 1
- 201000001430 Klinefelter's syndrome Diseases 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 229940105132 Myristate Drugs 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinylpyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 210000003739 Neck Anatomy 0.000 description 1
- 206010029410 Night sweats Diseases 0.000 description 1
- 229940095127 OLETH-20 Drugs 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 206010033165 Ovarian failure Diseases 0.000 description 1
- 210000001672 Ovary Anatomy 0.000 description 1
- ICMWWNHDUZJFDW-DHODBPELSA-N Oxymetholone Chemical compound C([C@@H]1CC2)C(=O)\C(=C/O)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 ICMWWNHDUZJFDW-DHODBPELSA-N 0.000 description 1
- 229940089513 PENTADECALACTONE Drugs 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229940071643 Prefilled Syringe Drugs 0.000 description 1
- 206010036601 Premature menopause Diseases 0.000 description 1
- 208000002500 Primary Ovarian Insufficiency Diseases 0.000 description 1
- 210000002307 Prostate Anatomy 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037175 Psychiatric disease Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038435 Renal failure Diseases 0.000 description 1
- 229940030484 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM ESTROGENS Drugs 0.000 description 1
- 210000004706 Scrotum Anatomy 0.000 description 1
- 206010059594 Secondary hypogonadism Diseases 0.000 description 1
- 210000003765 Sex Chromosomes Anatomy 0.000 description 1
- 206010070835 Skin sensitisation Diseases 0.000 description 1
- 229940083608 Sodium Hydroxide Drugs 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 229940037128 Systemic Glucocorticoids Drugs 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N TFA trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 206010043318 Testicular failure primary Diseases 0.000 description 1
- 229940051104 Testim Drugs 0.000 description 1
- 229960005353 Testolactone Drugs 0.000 description 1
- 229960004824 Triptorelin Drugs 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N Xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 229940048053 acrylate Drugs 0.000 description 1
- 230000037328 acute stress Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000003078 antioxidant Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N butylene glycol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940049638 carbomer homopolymer type c Drugs 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000005591 charge neutralization Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 201000000160 cryptorchidism Diseases 0.000 description 1
- 230000001186 cumulative Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 229940046080 endocrine therapy drugs Estrogens Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable Effects 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 230000003054 hormonal Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 230000001771 impaired Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 200000000018 inflammatory disease Diseases 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-M isobutyrate Chemical compound CC(C)C([O-])=O KQNPFQTWMSNSAP-UHFFFAOYSA-M 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000029849 luteinization Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 229960001566 methyltestosterone Drugs 0.000 description 1
- 230000003020 moisturizing Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000035498 noncompartmental analysis Effects 0.000 description 1
- 231100000539 ovarian failure Toxicity 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 230000000624 ovulatory Effects 0.000 description 1
- 229960005244 oxymetholone Drugs 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 230000035506 pharmacokinetic model Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-M phenylacetate Chemical compound [O-]C(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-M 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- 230000001817 pituitary Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 201000000926 premature ovarian failure Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 229960005335 propanol Drugs 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000001603 reducing Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000035489 relative bioavailability Effects 0.000 description 1
- 231100000812 repeated exposure Toxicity 0.000 description 1
- 230000001850 reproductive Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 231100000370 skin sensitisation Toxicity 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 230000000152 swallowing Effects 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- 229950003147 testosterone enantate Drugs 0.000 description 1
- VOCBWIIFXDYGNZ-IXKNJLPQSA-N testosterone enanthate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCC)[C@@]1(C)CC2 VOCBWIIFXDYGNZ-IXKNJLPQSA-N 0.000 description 1
- 229960003484 testosterone enanthate Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-M undecanoate Chemical compound CCCCCCCCCCC([O-])=O ZDPHROOEEOARMN-UHFFFAOYSA-M 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Abstract
613029 Disclosed is a transdermal or transmucosal formulation comprising: - 2% weight of testosterone, - C2 to C4 alkanol, - polyalcohol, and - a monoalkyl ether of diethylene glycol permeation enhancer, wherein said formulation comprises fatty alcohols, fatty acids, and fatty esters having a branched or linear acid moiety having 8 or more carbon atoms or having a branched or linear alcohol moiety having 8 or more carbon atoms in a total amount of less than 0.1% wt. a branched or linear acid moiety having 8 or more carbon atoms or having a branched or linear alcohol moiety having 8 or more carbon atoms in a total amount of less than 0.1% wt.
Description
TESTOSTERONE FORMULATIONS
FIELD OF THE INVENTION
The subject invention lies in the field of transdermal testosterone formulations.
BACKGROUND OF THE INVENTION
Systemic delivery of active agents across the skin or mucosal membrane is
convenient, pain-free, non-invasive and circumvents problems associated with the "first
pass effect". Such transdermal drug delivery is typically restricted to low-molecular
weight drugs and drugs with specific lipophilic/hydrophilic balance able to penetrate the
stratum corneum.
Transdermal drug delivery systems enable chemical modification of the barrier
properties of skin to effectively and efficiently permit penetration thereof. Known
drawbacks of transdermal delivery systems are, for example, the length of time needed
for penetration, frequent dosing regimen, and the volume size of a transdermal
composition needed to transdermally deliver a sufficient therapeutic amount of the
active agent. Due to e.g. the need for such a large dose volume, the composition applied
transdermally is inevitably maintained on the treated skin area for a long period of time,
thereby exposing the active agent to be transdermally delivered to degradation processes
and also exposing the immediate surroundings (e.g. clothing, spouses etc.) of the subject
treated to the active agent.
Testosterone is an androgen, anabolic steroid which is primarily secreted in the
testes of males and the ovaries of females, and in much smaller amounts by the adrenal
glands. In men, testosterone plays a key role in the development of male reproductive
tissues such as the testis and prostate, as well as promotes secondary sexual
characteristics such as increased muscle, bone mass and hair growth. In women,
testosterone plays a role in the development of pubic and axillary hair, sexual libido,
bone density, muscle tone, and vitality. Testosterone is essential for health and well-
being as well as the prevention of osteoporosis in both males and females.
Examples of known transdermal testosterone formulations for the treatment of
e.g. hypogonadism are FORTESTA® (TOSTRAN®/ TOSTREX®/ ITNOGEN®)
(ProStrakan Group plc), a 2% testosterone gel containing ethanol, propanol, propylene
glycol, carbomer, triethanolamine, purified water, butylhydroxytoluene and oleic acid,
TESTIM® (Auxilium Pharmaceuticals), a 1% testosterone gel containing
pentadecalactone, acrylate, carbomer, glycerin, polyethylene glycol (PEG), propylene
glycol, ethanol, tromethamine and water, and ANDROGEL® (TESTOGEL®) a 1%
testosterone gel containing ethanol, isopropyl myristate, carbomer, sodium hydroxide
and water.
US 7,198,801 and its patent family member disclose
formulations for transdermal or transmucosal administration of active agents, such as
testosterone, containing an alkanol, a polyalcohol, and a monoalkyl ether of diethylene
glycol. The formulations disclosed in US 7,198,801 are reported to be substantially
odor- and irritation-free as a result of the absence of long chain fatty alcohols, long-
chain fatty acids, and long-chain fatty esters in the formulations.
As any product of technology at all times, also the latter formulations are not
free of their own drawbacks and can further be improved upon. There is still a need for
a transdermal formulation that delivers therapeutically effective amounts of testosterone
in a controlled manner to subjects in need thereof, such formulation having high skin
tolerability, efficient and regulated skin absorption, enabling daily doses having lower
volumes and thus shorter administration regimens.
SUMMARY OF THE INVENTION
The present invention provides a transdermal or transmucosal formulation
comprising:
- 2%wt of testosterone, and
- a penetration enhancing system comprising: C to C alkanol, polyalcohol,
and monoalkyl ether of diethylene glycol,
wherein said formulation is substantially free of long-chain fatty alcohols, long-
chain fatty acids, and long-chain fatty esters.
The formulations of the invention provide controlled plasma levels of
testosterone and further enable a lower administration volume and thus shorter
administration regimens of treatment. Such controlled plasma levels achieved with a
formulation of the invention provide regulated transdermal or transmucosal delivery of
testosterone to a subject wherein plasmatic peaks of testosterone are reduced or
minimized, thereby avoiding the drawbacks and side effects of known formulations.
In one aspect the invention provides a transdermal or transmucosal formulation
comprising: 2% wt of testosterone, C to C alkanol, polyalcohol, and monoalkyl ether
of diethylene glycol, wherein said formulation is substantially free of long-chain fatty
alcohols, long-chain fatty acids, and long-chain fatty esters.
In another aspect the invention provides a transdermal or transmucosal
formulation comprising: 2% wt of testosterone, 44.0%wt of ethanol, 20.0%wt of
propylene glycol, and 5.0%wt of diethylene glycol monoethyl ether, wherein said
formulation is substantially free of long-chain fatty alcohols, long-chain fatty acids, and
long-chain fatty esters.
In a further aspect the invention provides a transdermal or transmucosal
formulation comprising: 2% wt of testosterone, 44.0%wt of ethanol, 20.0%wt of
propylene glycol, 5.0%wt of diethylene glycol monoethyl ether, 1.20%wt carbomer,
0.35%wt triethanolamine, 0.06%wt edetate disodium and water (q.s.) wherein said
formulation is substantially free of long-chain fatty alcohols, long-chain fatty acids, and
long-chain fatty esters.
In a further aspect the invention provides a transdermal or transmucosal
formulation consisting of 2% wt of testosterone, 44.0%wt of ethanol, 20.0%wt of
propylene glycol, 5.0%wt of diethylene glycol monoethyl ether, 1.20%wt carbomer,
0.35%wt triethanolamine, 0.06%wt edetate disodium and water (q.s.).
Furthermore, the present invention relates to a method for administering
testosterone to a mammal in need thereof, said method comprises transdermally
administering to a skin or mucosal membrane of said mammal a formulation of the
invention.
The invention further relates to a method of treating a disease or disorder
associated with reduced endogenous testosterone production, said method comprises
transdermally administering to a skin or mucosal membrane of a mammal a formulation
of the invention.
In another one of its aspects the invention provides a method of treating a
disease or disorder associated with reduced endogenous testosterone production in a
male subject, said method comprising transdermally administering to a skin or mucosal
membrane of a male subject a formulation comprising: 1 – 2%wt of testosterone, C to
C alkanol, 20.0%wt of propylene glycol, and monoalkyl ether of diethylene glycol,
wherein said formulation is substantially free of long-chain fatty alcohols, long-chain
fatty acids, and long-chain fatty esters.
In another one of its aspects the invention provides a method of treating a
disease or disorder associated with reduced endogenous testosterone production in a
male subject, said method comprises transdermally administering to a skin or mucosal
membrane of a male subject a formulation comprising: 1 – 2%wt of testosterone, C to
C alkanol, 20.0%wt of propylene glycol, monoalkyl ether of diethylene glycol, gelling
agent, neutralizing agent, chelating agent, and solvent, wherein said formulation is
substantially free of long-chain fatty alcohols, long-chain fatty acids, and long-chain
fatty esters.
In another one of its aspects the invention provides a method of treating a
disease or disorder associated with reduced endogenous testosterone production in a
male subject, said method comprising transdermally administering to a skin or mucosal
membrane of a male subject a formulation comprising 1 – 2%wt of testosterone, 44%wt
ethanol, 20.0%wt of propylene glycol, 5%wt of monoethyl ether of diethylene glycol,
1.2%wt carbomer, 0.35%wt triethanolamine, 0.06%wt edetate disodium and water (q.s.)
wherein said formulation is substantially free of long-chain fatty alcohols, long-chain
fatty acids, and long-chain fatty esters.
In another one of its aspects the invention provides a method of treating a
disease or disorder associated with reduced endogenous testosterone production in a
male subject, said method comprising transdermally administering to a skin or mucosal
membrane of a male subject a formulation consisting of 1 – 2%wt of testosterone,
44%wt ethanol, 20.0%wt of propylene glycol, 5%wt monoethyl ether of diethylene
glycol, 1.2%wt carbomer, 0.35%wt triethanolamine, 0.06%wt edetate disodium and
water.
In another aspect the invention provides a transdermal or transmucosal
formulation of the invention for use in the treatment of a disease or disorder associated
with reduced endogenous testosterone production.
The formulations of the invention were shown to provide controlled testosterone
plasma levels. The formulations of the invention further demonstrated favorable once
daily administration volumes as a result of which the administration time was
beneficially shortened, the amount of unabsorbed testosterone left on the skin of a
subject was minimized, the exposure of the surroundings to the testosterone was
minimized and the exposure of the testosterone to degradation processes was
minimized. Accordingly, formulations of the invention were shown to deliver
therapeutic amounts of testosterone by a convenient, clinically effective, user-friendly
and simplified dosing regimen.
BRIEF DESCRIPTION OF THE DRAWINGS
In order to understand the invention and to see how it may be carried out in
practice, embodiments will now be described, by way of non-limiting example only,
with reference to the accompanying drawings, in which:
Fig. 1 shows a flow chart of the preparation of a testosterone gel formulation of
the invention.
Figs. 2A-2B show the cumulated penetration profile (absolute kinetic profile, in
µg/cm , Fig. 2A) and the drug flux (in µg/cm h, Fig. 2B) of testosterone (see example
Figs. 3A-3B show the cumulated penetration profile (absolute kinetic profile, in
µg/cm , Fig. 3A) and the drug flux (in µg/cm h, Fig. 3B) of testosterone formulations in
in vitro study #1 (see example 3).
Figs. 4A-4B show the cumulated penetration profile (absolute kinetic profile, in
µg/cm , Fig. 4A) and the drug flux (in µg/cm h, Fig. 4B) of testosterone formulations in
in vitro study #2 (see example 3).
Figs. 5A-5B show the cumulated penetration profile (absolute kinetic profile, in
µg/cm , Fig. 5A) and the drug flux (in µg/cm h, Fig. 5B) of testosterone formulations in
in vitro study #3 (see example 3).
Figs. 6A-6B show the cumulated penetration profile (absolute kinetic profile, in
µg/cm , Fig. 6A) and the drug flux (in µg/cm h, Fig. 6B) of testosterone formulations in
in vitro study #4 (see example 3).
Figs. 7A-7B show the cumulated penetration profile (absolute kinetic profile, in
µg/cm , Fig. 7A) and the drug flux (in µg/cm h, Fig. 7B) of testosterone formulations in
in vitro study #5 (see example 3).
Figs. 8A-8B show the cumulated penetration profile (absolute kinetic profile, in
µg/cm , Fig. 8A) and the drug flux (in µg/cm h, Fig. 8B) of testosterone formulations in
in vitro study #6 (see example 3).
Fig.9 shows the cumulated penetration profile of testosterone formulations
tested (absolute kinetic profile, in µg/cm ) in example 4.
Fig.10 shows the drug flux (in µg/cm h) of testosterone formulations tested in
example 4.
Fig.11 shows the cumulated penetration profile of testosterone formulations
(absolute kinetic profile, in µg/cm ) tested in example 5.
Fig. 12 shows the in vivo testosterone plasma levels of a 2%wt testosterone
formulation compared to a 1%wt testosterone formulation over a period of 24h after the
last dosing (day 7) of each formulation in a treatment period (see example 6).
Fig. 13 is a demonstration of the volume amount of a 2%wt testosterone
formulation compared to a 1%wt testosterone formulation having similar testosterone
plasma levels (left: 5.4 grams of testosterone 1% gel, deemed therapeutically equivalent
to 10 grams ANDROGEL; right: 3.7 grams of a testosterone 2% gel, also deemed
therapeutically equivalent to 10 grams ANDROGEL) (see Example 7).
DETAILED DESCRIPTION OF EMBODIMENTS
In one of its aspects the invention provides a transdermal or transmucosal
formulation comprising 2% wt of testosterone and a penetration enhancing system
comprising C to C alkanol, polyalcohol and monoalkyl ether of diethylene glycol,
wherein said formulation is substantially free of long-chain fatty alcohols, long-chain
fatty acids, and long-chain fatty esters.
It should be noted that the selection of the types and amounts of the components
present in a formulation of the invention, other than testosterone, were based on several
factors, including, among others: potential for skin permeation of testosterone from a
formulation of the invention, ease of manufacturing, compatibility between the various
components of a formulation of the invention, and stability of a formulation of the
invention. It is furthermore noted that the components of the permeation enhancing
system as defined herein are present in an amount sufficient to provide permeation
enhancement of testosterone through dermal or mucosal surfaces.
Unless expressly specified otherwise, the term “comprising” is used in the
context of the present application to indicate that further members may optionally be
present in addition to the members explicitly mentioned. It is, however, contemplated as
a specific embodiment of the present invention that the term “comprising” encompasses
the possibility of no further members being present. In other words, for the purpose of
this embodiment, “comprising” is to be understood as having the meaning of
“consisting of”.
The following detailed description discloses specific and/or preferred variants of
the individual features of the invention. The present invention also contemplates as
particularly preferred embodiments those embodiments, which are generated by
combining two or more of the specific and/or preferred variants described for two or
more of the features of the present invention.
Unless expressly specified otherwise, all indications of relative amounts in the
present application are made on a weight/weight basis. Indications of relative amounts
of a component characterized by a generic term are intended to refer to the total amount
of all specific variants or members covered by said generic term. If a certain component
defined by a generic term is specified to be present in a certain relative amount, and if
this component is further characterized to be a specific variant or member covered by
the generic term, it is intended that no other variants or members covered by the generic
term are additionally present such that the total relative amount of components covered
by the generic term exceeds the specified relative amount, more preferably, in such
case, no other variants or members covered by the generic term are present at all.
When referring to a formulation comprising "2%wt testosterone", such
formulation should be understood to allow for a pharmaceutically acceptable variation
in the %wt of testosterone. In the context of this invention, a pharmaceutically
acceptable variation ranges from 1.9%wt testosterone to 2.1%wt testosterone.
The terms "transdermal formulation" or "transmucosal formulation" should be
understood to encompass a formulation of the invention capable of delivering
testosterone to a mammal administered with said formulation, by permeating the
testosterone through the skin or mucosal tissue (or membrane), said formulation being
topically applied and entering into the bloodstream of said mammal.
"Transdermal delivery" as used herein should be understood to encompass
transdermal, percutaneous and transmucosal administration, i.e. delivery by
passage/permeation of a drug through the skin or mucosal tissue into the bloodstream.
The term "skin" or "skin tissue" or "skin membrane" as used herein
interchangeably should be understood to encompass any dermal membrane (including
any epidermis or dermis layer of a skin membrane), including any hairy or glabrous
cutaneous membrane.
The term "mucosa" or "mucosal tissue" or "mucosal membrane" as used herein
interchangeably should be understood to encompass any moist anatomical membrane or
surface on a mammal that can be permeated without swallowing such as oral, buccal,
auricular, vaginal, rectal, nasal or ophthalmic surfaces.
The term "topical" or "topically" is used herein as referring to direct contact of a
formulation of the invention, with a surface area on a mammal including any portion of
a skin membrane or mucosal membrane.
The term "mammal" as used herein should be understood to encompass any
mammal. In one embodiment, the mammal is a human mammal. In another
embodiment, the mammal is a male human. In yet another embodiment, the mammal is
a female human.
When referring to testosterone, it should be understood to refer to the androgen
steroidal hormone 17- -hydroxyandrostenone also named
(8R, 9S, 10R, 13S, 14S, 17S)hydroxy-10,13-dimethyl-
1,2,6,7,8,9,11,12,14,15,16,17dodecahydrocyclopenta[a]phenanthrenone (CAS
Registry Number 580).
Examples of other androgens which may be used in a transdermal or
transmucosal formulation of the invention include, but are not limited to, any esters of
testosterone (such as testosterone enanthate, propionate, cypionate, phenylacetate,
acetate, isobutyrate, buciclate, heptanoate, decanoate, undecanoate, caprate and
isocaprate esters), 4-dihydrotestosterone, and any pharmaceutically acceptable
derivatives of testosterone such as for example methyl testosterone, testolactone,
oxymetholone and fluoxymesterone. These androgens may be used singly or in
combinations of two or more thereof.
As noted hereinabove, a formulation of the invention is substantially free of
long-chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters. Such an
omission of long chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters
provides a formulation that does not have an unpleasant odor, irritation, and/or greasy
texture caused by formulations that include one or more of such compounds, resulting
in greater patient compliance.
"Long-chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters" as used
herein should be understood to encompass fatty alcohols and fatty acids having a
branched or linear carbon body having 8 or more carbon atoms, and esters thereof, i.e.
fatty esters having a branched or linear acid moiety having 8 or more carbon atoms or
having a branched or linear alcohol moiety having 8 or more carbon atoms.
"substantially free of long-chain fatty alcohols, long-chain fatty acids, and long-
chain fatty esters" as used herein should be understood to mean comprising fatty
alcohols, fatty acids and/or fatty esters in a total amount of less than about 0.1%wt.
The invention thus provides a transdermal or transmucosal formulation
comprising 2% wt of testosterone, C to C alkanol, polyalcohol and monoalkyl ether of
diethylene glycol, wherein said formulation is substantially free of long-chain fatty
alcohols, long-chain fatty acids, and long-chain fatty esters.
In one embodiment a transdermal or transmucosal formulation of the invention
further comprises at least one of a gelling agent, a neutralizing agent, a chelating agent
and a solvent or any combinations thereof.
For example, in one embodiment a transdermal or transmucosal formulation of the
invention comprises 2% wt of testosterone, C to C alkanol, polyalcohol, monoalkyl
ether of diethylene glycol and gelling agent. In another embodiment a transdermal or
transmucosal formulation of the invention comprises 2% wt of testosterone, C to C
alkanol, polyalcohol, monoalkyl ether of diethylene glycol, gelling agent and
neutralizing agent. In a further embodiment a transdermal or transmucosal formulation
of the invention comprises 2% wt of testosterone, C to C alkanol, polyalcohol,
monoalkyl ether of diethylene glycol, gelling agent, neutralizing agent and chelating
agent. In yet another embodiment a transdermal or transmucosal formulation of the
invention comprises 2% wt of testosterone, C to C alkanol, polyalcohol, monoalkyl
ether of diethylene glycol, gelling agent, neutralizing agent, chelating agent and solvent.
It is envisaged that a formulation of the invention comprises C -C alkanol in an
amount between about 5 – 50%wt (e.g. about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50%wt),
polyalcohol in an amount between about 1 – 30%wt (e.g. about 1, 2, 3, 4, 5, 10, 15, 20,
, 30%wt), monoalkyl ether of diethylene glycol in an amount of between about 0.2 –
%wt (e.g. about 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0,
9.0, 10.0, 15, 20, 25%wt), gelling agent in an amount between about 0.05 – 4%wt (e.g.
about 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.5, 2, 2.5,
3. 3.5, 4%wt), neutralizing agent in an amount between about 0.05 – 1 %wt (e.g. about
0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1%wt) and chelating
agent in an amount between about 0.001 – 5.0%wt (e.g. about 0.001, 0.002, 0.003,
0.004, 0.005, 0.006, 0.007, 0.008, 0.009, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08,
0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4, 4.5, 5.0%wt) .
A "penetration enhancing system" as used herein should be understood to
comprise C to C alkanol, polyalcohol and monoalkyl ether of diethylene glycol, which
together qualitatively and/or quantitatively enhance the absorption and/or penetration of
testosterone of a formulation of the invention through a skin or mucosal membrane of a
mammal administered with said formulation (as compared with the transdermal delivery
of testosterone without said penetration enhancing system).
The term "C to C alkanol" as used herein should be understood to encompass
one or more C to C alkanes substituted with a hydroxy group (–OH).
In one embodiment, an alkanol utilized by a formulation of the invention is one
or more selected from the group consisting of ethanol, isopropanol and n-propanol. In
another embodiment said alkanol is ethanol. In a further embodiment, said alkanol is
ethanol present in an amount of about 44.0%wt in a formulation of the invention.
In some embodiments an alkanol is also utilized by a formulation of the
invention (such as for example ethanol) as the primary solvent for the testosterone in a
formulation of the invention. The quantity of the alkanol should be sufficient to at least
fully solubilise the testosterone. Additionally, alkanols, such as ethanol, are known to be
efficient skin permeation enhancers which act by extracting polar stratum corneum
lipids and, consequently, increase partitioning for numerous drug substances. However,
as demonstrated herein below (see example 1), the inventors of the present invention
found that in order to enhance the penetration of a formulation of the invention, said
alkanol (e.g. ethanol) may be present in a formulation of the invention in amounts of up
to 50%wt, and in a particular embodiment in an amount of up to 44%wt.
In some embodiments, a formulation of the invention comprises alkanol in a
hydroalcoholic mixture with water.
In the context of the present invention, the term "polyalcohol" as used herein
should be understood to encompass one or more of a C to C alkane or C to C alkene,
2 6 2 6
substituted with two or more hydroxy groups.
In some embodiments, a polyalcohol comprised in a formulation of the
invention is one or more selected from the group consisting of ethylene glycol,
propylene glycol, butylene glycol, and hexylene glycol. In one embodiment a
polyalcohol comprised in a formulation of the invention is propylene glycol. In another
embodiment a formulation of the invention comprises propylene glycol in an amount of
about 20.0%wt.
The term "monoalkyl ether of diethylene glycol" as used herein should be
understood to encompass one or more diethylene glycols substituted with a C to C
alkyl ether.
In one embodiment, monoalkyl ether of diethylene glycol comprised in a
formulation of the invention is one or both of diethylene glycol monoethyl ether
(DGME) and diethylene glycol monomethyl ether. In another embodiment, a
formulation of the invention comprises diethylene glycol monoethyl ether. In yet
another embodiment, a formulation of the invention comprises diethylene glycol
monoethyl ether in an amount of about 5.0%wt.
The term "gelling agent" as used herein should be understood to encompass any
agent capable of altering the viscosity of a formulation. A gelling agent used in a
formulation of the invention can be one or more selected from the group including:
carbomer, carboxyethylene or polyacrylic acid such as carbomer or carbopol 980NF
(CARBOPOL 980 NF) or 940 NF, 981 or 941 NF, 1382 or 1342 NF, 5984 or 934
NF, ETD 2020, 2050, 934P NF, 971P NF, 974P NF, Ultrez 10 NF, Pemulen TR-1 NF
or TR-2 NF and Noveon AA-1 USP, cellulose derivatives such as ethylcellulose (EC),
hydroxypropylmethylcellulose (HPMC), ethylhydroxyethylcellulose (EHEC),
carboxymethylcellulose (CMC), hydroxypropylcellulose (HPC) (Klucel different
grades), hydroxyethylcellulose (HEC) (Natrosol grades), HPMCP 55, and Methocel
grades, natural gums such as arabic, xanthan, guar gums, and alginates,
polyvinylpyrrolidone derivatives such as Kollidon grades, polyoxyethylene-
polyoxypropylene copolymers such as Lutrol F grades 68 and 127, chitosan, polyvinyl
alcohols, pectins, and veegum grades. A tertiary amine, such as triethanolamine or
trolamine, can be included to thicken and neutralize the system.
In one embodiment, the gelling agent comprised in a formulation of the
invention is a carbomer. Carbomer relates to a class of homopolymers of acrylic acid
with a high molecular weight, which are cross-linked with any of several polyalcohol
allyl ethers. Non-limiting examples of carbomers are carbomer 940, carbomer 973,
carbomer 980NF, and carbomer C981 NF (wherein the digit indicates the average
molecular weight of the polymer chains). In a particular embodiment, the gelling agent
comprised in a formulation of the invention is carbomer C980NF. In yet another
embodiment, the gelling agent comprised in a formulation of the invention is carbomer
C980NF in an amount of 1.20%wt.
The term "neutralizing agent" as used herein should be understood to encompass
one or more agents capable of neutralizing an acidic or basic component of a
formulation of the invention in order to achieve a stable and homogeneous formulation.
Non-limiting examples of a neutralizing agent include: diethylamine, diisopropylamine,
a ternary amine such as triethanolamine or tromethamine,
tetrahydroxypropylethylendiamine, and alkalis such as KOH or NaOH solution. For
example, neutralization of hydro-alcoholic gels containing carbomer polymer can be
accomplished using different bases. The salt of the carbomer polymer must be swellable
in the solvent system, otherwise it will precipitate and no thickening effect will occur.
Triethanolamine can be used in hydro-alcoholic gels with up to 50% alcohol.
In one embodiment, a neutralizing agent comprised in a formulation of the
invention is triethanolamine (also named trolamine interchangeably). In another
embodiment, a neutralizing agent comprised in a formulation of the invention is
triethanolamine in an amount of about 0.35%wt. This concentration of triethanolamine
(0.35% wt) in a formulation of the invention provides a pH level of between about 5.6
to about 6.8.
The term "chelating agent" as used herein should be understood to encompass
one or more agents which complex and segregate residual traces of free multivalent
cations susceptible to cause the physical degradation of the gel matrix (thereby causing
loss of viscosity and breakdown of the formulation). Chelating agents provide improved
physical stability and robustness of a formulation of the invention.
In one embodiment, a chelating agent comprised in a formulation of the
invention is edetate disodium. In further embodiments, a chelating agent comprised in a
formulation of the invention is edetate disodium in an amount of about 0.06%wt.
As used herein the term "solvent" may encompass any type of solvent suitable
for use in a transdermal or transmucosal formulation of the invention, and may be the
same or different than any other component of a formulation of the invention, as
detailed herein above.
In one embodiment, a solvent comprised in a formulation of the invention is
water.
The invention further provides a transdermal or transmucosal formulation
comprising: 2% wt of testosterone, 44.0%wt of ethanol, 20.0%wt of propylene glycol,
and 5.0%wt of diethylene glycol monoethyl ether, wherein said formulation is
substantially free of long-chain fatty alcohols, long-chain fatty acids, and long-chain
fatty esters.
The subject invention specifically provides a transdermal or transmucosal
formulation comprising: 2% wt of testosterone, 44.0%wt of ethanol, 20.0%wt of
propylene glycol, 5.0%wt of diethylene glycol monoethyl ether, 1.20%wt of carbomer,
0.35%wt of triethanolamine, 0.06%wt of edetate disodium and water (q.s.) wherein said
formulation is substantially free of long-chain fatty alcohols, long-chain fatty acids, and
long-chain fatty esters.
The subject invention further provides a transdermal or transmucosal
formulation consisting of 2% wt of testosterone, 44.0%wt of ethanol, 20.0%wt of
propylene glycol, 5.0%wt of diethylene glycol monoethyl ether, 1.20%wt of carbomer,
0.35%wt of triethanolamine, 0.06%wt of edetate disodium and water (q.s.).
In a specific embodiment, the carbomer is carbomer C980 NF. In another
specific embodiment carbomer C980NF is present in an amount of 1.20%wt in a
formulation of the invention.
The subject invention thus provides an advanced transdermal permeation
enhancing system, comprising a combination of volatile solvent (e.g. ethanol) and non-
volatile cosolvents (e.g. propylene glycol and e.g. diethylene glycol monoethyl ether),
embedded in an aqueous gel matrix of acrylic polymer.
In some embodiments a formulation of the invention further comprises at least
one of a buffering agent, moisturizing agent, humectant, surfactant, antioxidant,
emollient, or buffer.
In some other embodiments, a formulation of the invention is in the form of a
gel, lotion, cream, spray, aerosol, ointment, emulsion, suspension, liposomal system,
lacquer, patch, bandage, buccal tablet, wafer, sublingual tablet, suppository, vaginal
dosage form or occlusive dressing. In a particular embodiment, the formulation is a gel.
In other embodiments, a formulation of the invention is in the form of at least
one of the following: a clear (invisible) formulation, a water washable formulation, a
cool-to-the-touch formulation, a quick-drying formulation, a spreadable formulation and
a non-greasy formulation.
In some embodiments said formulation is in the form of a gel. In other
embodiments, said formulation is in the form of a clear invisible gel.
In some embodiments, a formulation of the present invention is applied directly
to the skin by, for example a gel, an ointment, or a cream or indirectly through a patch,
bandage, or other occlusive dressing.
A transdermal formulation of the invention may be topically applied to any body
part, such as to the chest, thigh, abdomen, shoulder, upper arm, upper torso, back, neck,
feet, hands, axilla, or scrotum. In one embodiment, a formulation of the invention is
applied to the abdomen. In another embodiment, a formulation of the invention is
applied to the abdomen once a day. In another embodiment, a formulation of the
invention is applied to the upper arm. In another embodiment, a formulation of the
invention is applied to the upper arm once a day.
In one embodiment, a formulation in the form of a gel is applied to an area of
skin of from about 100cm up to about 1500cm , so that testosterone is applied e.g. at
about 50 micrograms per square centimeter of skin. Application may be to alternate
areas of the body as applications alternate. This may be advantageous in alleviating any
sensitivity of the skin to repeated exposure to components of the formulation.
A formulation of the invention may be applied once daily, or multiple times per
day depending upon the condition of the patient.
In some embodiments, a formulation of the invention is adapted for transdermal
or transmucosal administration according to a schedule (dosing regimen) having a
periodicity selected from once to five times daily dosing, once-weekly dosing or bi-
weekly dosing.
In some embodiments, said formulation is adapted for a once daily transdermal
or transmucosal administration. In other embodiments, said formulation is adapted for a
once daily transdermal or transmucosal administration to the abdomen (or a portion
thereof) of a mammal in need thereof. In yet other embodiments, said formulation is
adapted for a once daily transdermal or transmucosal administration to the upper arm
(or a portion thereof) of a mammal in need thereof.
The present invention further provides a method for administering testosterone
to a mammal in need thereof which comprises transdermally administering to a skin or
mucosal membrane of a mammal a formulation of the invention. It is envisaged that the
administration is for the treatment of diseases and disorders associated with reduced
endogenous testosterone production.
In another aspect the invention provides a method of treating a disease or
disorder associated with reduced endogenous testosterone production, said method
comprises transdermally administering to a skin or mucosal membrane of a mammal a
formulation of the invention.
In another one of its aspects the invention provides a method of treating a
disease or disorder associated with reduced endogenous testosterone production in a
male subject, said method comprising transdermally administering to a skin or mucosal
membrane of a male subject a formulation comprising: 1 – 2%wt of testosterone, C to
C alkanol, 20.0%wt of propylene glycol, and monoalkyl ether of diethylene glycol,
wherein said formulation is substantially free of long-chain fatty alcohols, long-chain
fatty acids, and long-chain fatty esters.
In a further aspect the invention provides a method of treating a disease or
disorder associated with reduced endogenous testosterone production in a male subject,
said method comprises transdermally administering to a skin or mucosal membrane of a
male subject a formulation comprising: 1 – 2%wt of testosterone, C to C alkanol,
.0%wt of propylene glycol, monoalkyl ether of diethylene glycol, gelling agent,
neutralizing agent, chelating agent and solvent wherein said formulation is substantially
free of long-chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters.
In a specific embodiment, the invention provides method of treating a disease or
disorder associated with reduced endogenous testosterone production in a male subject,
said method comprising transdermally administering to a skin or mucosal membrane of
a male subject a formulation comprising 1 – 2%wt of testosterone, 44%wt ethanol,
.0%wt of propylene glycol, 5%wt of monoethyl ether of diethylene glycol, 1.2%wt of
carbomer, 0.35%wt of triethanolamine, 0.06%wt of edetate disodium and water (q.s.)
wherein said formulation is substantially free of long-chain fatty alcohols, long-chain
fatty acids, and long-chain fatty esters.
In a specific embodiment, the invention provides method of treating a disease or
disorder associated with reduced endogenous testosterone production in a male subject,
said method comprising transdermally administering to a skin or mucosal membrane of
a male subject a formulation consisting of 1 – 2%wt of testosterone, 44%wt of ethanol,
.0%wt of propylene glycol, 5%wt of monoethyl ether of diethylene glycol, 1.2%wt of
carbomer, 0.35%wt of triethanolamine, 0.06%wt of edetate disodium and water (q.s.).
In another aspect, the invention provides a transdermal or transmucosal
formulation of the invention for use in the treatment of a disease or disorder associated
with reduced endogenous testosterone production.
In the context of the invention “diseases and disorders associated with reduced
endogenous testosterone production” should be understood to encompass any disease or
disorder which is directly or indirectly related to a condition of a mammalian subject
wherein the endogenous production of testosterone is either reduced or substantially
non-existent or terminated.
In one embodiment of the invention, diseases and disorders associated with
reduced endogenous testosterone production relate to hormonal disorders such as for
example hypogonadism, female sexual disorder, hypoactive sexual disorder, and
adrenal insufficiency.
In some embodiments, administration of a formulation of the invention
decreases the frequency of at least one of the clinical symptoms of a disease or disorder
associated with reduced endogenous testosterone production being treated such as hot
flashes, night sweats, decreased libido, osteoporosis and so forth.
For human males, diseases and disorders associated with reduced endogenous
testosterone production may lead to serum testosterone concentrations of less than a
concentration selected from 500 ng/dL, 300ng/dL, 100ng/dL, 50ng/dL and 10ng/dL.
Such conditions include, but are not limited to primary hypogonadism (primary
testicular failure) and secondary hypogonadism.
Major causes of primary hypogonadism include: abnormality in the testicles,
Klinefelter's syndrome, a congenital abnormality of the sex chromosomes X and Y,
undescended testicles, hemochromatosis, high levels of iron in the blood, injury to the
testicles, prior hernia surgery, cancer treatment and normal aging.
Major causes of secondary type of male hypogonadism include: defects in the
pituitary gland connected to the brain that controls hormone production, impaired
testicular function (sometimes caused by defects in the chemical messages from the
pituitary gland to the testicles), inflammatory diseases, and the use of certain drugs
(such as for example drugs for the treatment of psychiatric disorders and gastro-
oesophageal reflux disease) and ageing.
Additional “diseases and disorders associated with reduced endogenous
testosterone production” are testosterone deficiency, infertility, impotence, decreased
sexual desire, fatigue, loss of energy, mood depression, regression of secondary sexual
characteristics, muscle weakness and osteoporosis.
In one embodiment, said disease or disorder associated with reduced
endogenous testosterone production is hypogonadism.
In some embodiments, a formulation of the invention is administered to a male
mammal in order to provide said mammal with a therapeutically effective dosage of
testosterone of about 50 mg/day, thereby providing a male subject with a free serum
concentration of testosterone ranging from at least about 300 to about 1000 ng/dL.
In addition to the above, a formulation of the invention may, in some
embodiments be administered to a female in need thereof.
In some embodiments, a female undergoing treatment with a formulation of the
invention may be of childbearing age or older, in whom androgen production has been
interrupted either because of natural menopause, surgical procedures, radiation,
chemical ovarian ablation or extirpation, or premature ovarian failure. In addition, a
decline in endogenous testosterone in female subjects may be attributed to conditions
that suppress adrenal androgen secretion (i.e., acute stress, anorexia nervosa, Cushing's
syndrome, and pituitary renal insufficiency), conditions that can decrease ovarian
androgen secretion (i.e., ovarian failure and the use of pharmacologic doses of
glucocorticoids), and chronic illness such as muscle-wasting diseases like Acquired
Immune Deficiency Syndrome (AIDS).
Furthermore, reduced levels of testosterone in female subjects may lead to
female sexual dysfunction (FSD) resulting in clinical symptoms such as lack of sex
drive, arousal or pleasure, low energy, reduced sense of well-being and osteoporosis.
Therefore, some of the results of using a formulation of the invention to treat FSD in
female subjects may include one or more of the following: increased energy, increased
sense of well-being, decreased loss of calcium from bone, and increased sexual activity
and desires.
In pre-menopausal women, total plasma testosterone concentrations generally
range from 15-65 ng/dL (free testosterone in pre-menopausal women is approximately
1.5 to 7 pg/ml) and fluctuate during the menstrual cycle, with peaks of androgen
concentration corresponding to those of plasma estrogens at the pre-ovulatory and luteal
phases of the cycle. In the years leading to postmenopausal transition, levels of
circulating androgens begin to decline as a result of age-related reductions of both
ovarian and adrenal secretion. There are reports in studies that 24-hour mean plasma
testosterone levels in normal pre-menopausal women in their 40's are half that of
women in their early 20's. It has been generally accepted, however, that women with
androgen deficiency have total plasma testosterone levels less than 25 ng/dL ( less than
50-years-old) or less than 20 ng/dL (greater than or equal to 50-years-old) while
oophorectomized women can have total plasma testosterone levels less than 10 ng/dL.
In some embodiments a formulation of the invention is administered to a female
in order to provide her with a daily therapeutically effective dosage of testosterone of
about 1 mg to about 3 mg. In some embodiments a formulation of the invention
provides a female subject with a total serum concentration of testosterone from at least
about 15 to about 55 ng/dL, or a free serum concentration of testosterone from about 2
to about 7 pg/mL.
In some embodiments of a method of the invention, a formulation of the
invention is administered in combination with another treatment, such as, but not
limited to, estrogen replacement therapy (ERT), or any other drug or non-medical
treatment. Such administration of other therapies may be administered prior to
administration of a formulation of the invention, subsequent to administration of a
formulation of the invention, or simultaneous with administration of a formulation of
the invention, or any other treatment schedule prescribed by a healthcare provider.
In a further aspect the invention provides a kit comprising at least one container
comprising a formulation of the invention, and instructions for use thereof.
In some embodiments, a kit of the invention comprises a container which is
adapted for dispensing a predetermined measured amount of said formulation.
EXAMPLES
The invention is further described in the following examples, which are not in
any way intended to limit the scope of the inventions as claimed.
EXAMPLE 1: Preparation of testosterone gel formulations 1%wt and 2%wt
The 1%wt and 2%wt testosterone formulations were prepared by methods
known in the art, as schematically shown in Figure 1. The preparation was carried out in
controlled environment under continuous vacuum and nitrogen blanketing with
temperature control into a stainless steel planetary mixer.
Table 1 demonstrates a 10-kg batch preparation of a 1%wt testosterone gel
formulation. Table 2 demonstrates a 10-kg batch preparation of a 2%wt testosterone gel
formulation.
Table 1 – Batch Formula of Testosterone Gel 1%
Batch Size: 10 kg
Component Amount per batch
Testosterone 100.0 g
Ethanol 96% v/v (expressed as
4400 g
ethanol, anhydrous)
Propylene glycol 2000 g
Diethylene glycol monoethyl ether 500 g
Carbomer 980 120 g
Trolamine 35 g
Edetate disodium 6 g
Purified water up to 10 kg
Table 2 – Batch Formula of Testosterone Gel 2%
Batch Size: 10 kg
Component Amount per batch
Testosterone 200.0 g
Ethanol 96% v/v (expressed as
4400 g
ethanol, anhydrous)
Propylene glycol 2000 g
Diethylene glycol monoethyl ether 500 g
Carbomer 980 120 g
Trolamine 35 g
Edetate disodium 6 g
Purified water up to 10 kg
All experiments herein below were performed using formulations prepared
essentially as described in Example 1.
A. IN VITRO EXAMPLES
General Protocol and Measurements
All in vitro experiments were performed using fresh skin pieces (pig ear, human
skin) mounted on standard Franz-type vertical diffusion cells (Hanson Research Inc.).
Drug loading was approximately 5.6 mg gel/cm (as per OECD guidance no. 28,
Paris, December 2000), except indicated otherwise.
Temperature was maintained at 35°C throughout the duration of the skin
permeation study (24 hours).
Cumulative drug amounts permeated over 24 hours (µg/cm²) were determined
by High Pressure Liquid Chromatography techniques.
Example 2: Effect of alcohol concentration on penetration of testosterone
Table 1 below provides the formulations used for assessing the effect of the
alkanol levels on the penetration of a testosterone formulation of the invention.
Table 3 – Testosterone formulations used in Example 1
Component Formulation 1 Formulation 2
Testosterone 1.00% wt 1.00% wt
Ethanol, anhydrous 53.0% wt 69.0% wt
Carbomer 980 1.20% wt 1.20% wt
Edetate disodium 0.06% wt 0.06% wt
Trolamine 0.35% wt 0.35% wt
Purified water up to 100 % wt up to 100 % wt
Figs. 2A-2B show the cumulated penetration profile (absolute kinetic profile,
Fig. 2A) and the drug flux (Fig. 2B) of testosterone. These results suggest that there is
no need to increase ethanol concentration above approximately 50% wt, a level beyond
which increasing ethanol concentration does not result in skin penetration enhancement.
Additionally, ethanol levels higher than about 50% w/w may cause severe side effects
such as skin sensitization (skin dryness, redness, and itching), especially in cases where
the topical application is chronic, e.g. once-daily for several months to several years.
Example 3: Effect of penetration enhancing system
Different concentrations of the components of the permeation enhancing system
(comprising ethanol, propylene glycol and DGME) comprised in formulations of the
invention were tested for optimized maximal absorption of testosterone through the
skin. Tables 4 and 5 below list the formulations tested. These formulations were
compared with the absorption observed for the product ANDROGEL®.
Table 4 – Formulation Components (Results shown in Figs. 3-8, for Studies #1-6
respectively)
ANDROGEL® Testosterone Gel 1% Testosterone Gel 1% Testosterone Gel 2%
Components
Batch 1 Batch 2 Batch 3 Batch 4
Testosterone 1.00% wt 1.00% wt 1.00% wt 2.00% wt
Ethanol,
67.0% wt 47.5% wt 44.0% wt 44.0% wt
anhydrous
Isopropyl
0.50% wt - - -
myristate
DGME - 5.00% wt 5.00% wt 5.00% wt
Propylene
- 20.0% wt 20.0% wt 20.0% wt
glycol
Carbomer
0.90% wt 1.20% wt 1.20% wt 1.20% wt
C980
Sodium
4.72% wt - - -
hydroxide
Trolamine - 0.35% wt 0.35% wt 0.35% wt
Edetate
- 0.06% wt 0.06% wt 0.06% wt
disodium
Purified water up to 100 %wt up to 100 % wt up to 100 % wt up to 100 % wt
In vitro skin permeation studies #1 – 6 are shown in Figs. 3 to 8 and are also
summarized in Tables 5 and 6 below:
Table 5 - Cumulated testosterone permeated [%] after 24 hours
Study # #1 #2 #3 #4 #5 #6
ANDROGEL® 1.67 1.11 1.40 1.31 1.00 2.17
Testosterone Gel 1% 3.93 3.76 3.34 2.55 4.42 9.82
Testosterone Gel 2% 4.56 4.07 5.06 3.37 3.65 8.21
Table 6 – Maximal testosterone instant flux [mg/cm h]
Study # #1 #2 #3 #4 #5 #6
ANDROGEL® N/A 0.04 (19H) 0.07 (19H) N/A N/A 0.07 (9H)
Testosterone Gel 1% 0.13 (14H) 0.14 (14H) 0.15 (9H) 0.12 (14H) 0.17 (14H) 0.39 (9H)
Testosterone Gel 2% 0.31 (14H) 0.28 (14H) 0.20 (14H) 0.22 (19H) 0.27 (14H) 0.67 (9H)
The results of in vitro study #1 (Figs. 3A-3B and Tables 5 and 6) show that at
1% testosterone strength (Table 4, batch 3), the penetration enhancing system of the
formulation enabled a skin penetration of testosterone which is 2.4-fold higher than skin
penetration of ANDROGEL® (Table 4, batch 1). Doubling testosterone strength (from
1% wt to 2% Table 4, batch 4) led to a further 2.3-fold increase of skin penetration of
testosterone.
The results of in vitro study #2 (Figs. 4A-4B and Tables 5 and 6) show that the
use of a penetration enhancing system (Table 4, batches 2 and 4) as defined herein
above provides improved skin penetration results as compared with the ANDROGEL®
(Table 4, batch 1). Doubling the testosterone strength from 1%wt to 2%wt and lowering
the concentration of the alkanol (from 47.5%wt in batch 2 to 44%wt in batch 3)
provided enhanced penetration results.
The results of in vitro studies #3 - 6 (Figs. 5 - 8 and Tables 5 and 6) show that
the use of a penetration enhancing system (Table 4, batch 3) as defined herein above
provides improved skin penetration results as compared with the ANDROGEL® (batch
1). Doubling the testosterone strength (from 1%wt in batch 3 to 2%wt in batch 4)
provided enhanced instant testosterone flux results (Table 6 and Figs. 5B, 6B, 7B and
8B).
Example 4: Effect of dose volume on testosterone penetration
The following formulations were tested for in vitro testosterone penetration:
Testosterone gel 1%, 10mg gel (0.1mg testosterone) applied per cell.
Testosterone gel 1%, 20mg gel (0.2mg testosterone) applied per cell.
Testosterone gel 2%, 10mg gel (0.2mg testosterone) applied per cell.
All formulations contained the following additional components: 44.0%wt of
ethanol, 20.0%wt of propylene glycol, 5.0%wt of diethylene glycol monoethyl ether,
1.20%wt of carbomer C980 NF, 0.35%wt of triethanolamine, 0.06%wt of edetate
disodium and water (q.s.).
Each test formulation was tested in 4 replicates (4 different skin donors).
Overall, twelve skin samples were used. Thickness of each sample was measured with a
micrometer. The samples were consequently mounted on vertical glass Franz diffusion
cells with a receptor compartment of about 7.5 mL, a donor compartment of 3.0 mL and
a diffusion area of 1.77 cm².
Phosphate buffered saline (PBS) at pH 7.4 with addition of 2% w/v oleth-20, i.e.
oleyl ether of polyoxyethylene glycol (VOLPO™ 20 or BRIJ™ 98, now BRIJ™ O20),
was used as receptor solution, maintained at 35°C during the whole study, and stirred at
600 RPM. The study was performed using a Microette® autosampler. After 2 hours pre-
incubation of the skin samples with the receptor solution, and integrity assessment by
evaporimetry, about 10 mg (5.65 mg/cm²) or 20 mg (11.3 mg/cm²) of the tested
formulation was applied with the tip of a plastic syringe plunger and gently spread over
the diffusion surface. Diffusion of the drug was allowed in non-occluded conditions
during 24 hours. Receptor solution samples (1.2 mL) were removed after 9 hours, 14
hours, 19 hours, and 24 hours (after 0.8 mL receptor compartment priming). The
samples were collected in 2 mL HPLC amber glass vials pre-sealed with septum crimp-
caps and pre-filled with 10 µL of a solution of trifluoroacetic acid (TFA) 10%. Then
samples were transferred into Eppendorf microtubes, and were centrifuged at 13500
RPM (SIGMA 2-16 P centrifuge) during 10 min. Each supernatant (0.9 mL) was
transferred in a 2mL HPLC amber glass vial. Analysis of the samples was performed by
HPLC.
Figure 9 shows that the 2% sample provided superior skin permeation of
testosterone compared to the 1% sample when keeping the same gel loading per unit
area (5.6mg/cm ):
(i) the absolute cumulated amount of testosterone permeated after 24 hours was
1.6 times higher (3.227µg/cm² versus 2.06 µg/cm² ) with the 2% sample;
(ii) the maximal testosterone instant flux was 1.7 times higher (0.209µg/cm²
versus 0.123µg/cm²) with the 2% sample;
(iii) the testosterone instant flux at 24 hours was 1.9 times higher (0.130µg/cm²
versus 0.070µg/cm²) with the 2% sample;
Figure 9 further shows that doubling the amount of T Gel 1% applied per cm from
about 5.6 mg/cm² to about 11.2 mg/cm², i.e. when doubling the amount of testosterone
applied per cm from about 56 µg/cm² to about 112 µg/cm², the absolute cumulated
amount of testosterone permeated after 24 hours was almost tripled (6.11µg/cm² versus
2.06 µg/cm²).
Figure 10 shows that the maximum testosterone flux of penetration when
loading 10 mg of the 2% sample applied over 1.77cm² (2% testosterone/5.6mg/cm²) was
obtained after 19 hours whereas the maximum testosterone flux of penetration when
loading 20mg of the 1% sample applied over 1.77cm² (1% testosterone/11.2mg/cm²)
was obtained after 14 hours. This was all the more surprising because Figure 10 also
shows that increasing testosterone loading of the 1% sample from 5.6µg/cm² to
11.2µg/cm² did not affect the time at which the maximal instant flux occurred (14
hours).
Example 5: Effect of Propylene Glycol concentration on testosterone
penetration
The following formulations were tested for in vitro testosterone penetration:
Testosterone gel 1%, containing 15% wt propylene glycol.
Testosterone gel 1%, containing 20% wt propylene glycol.
Testosterone gel 2%, containing 15% wt propylene glycol.
Testosterone gel 2%, containing 20% wt propylene glycol.
All formulations contained the following additional components: 44.0%wt of
ethanol, 20.0%wt of propylene glycol, 5.0%wt of diethylene glycol monoethyl ether,
1.20%wt of carbomer C980 NF, 0.35%wt of triethanolamine, 0.06%wt of edetate
disodium and water (q.s.).
Each test formulation was tested in 3 replicates (3 different skin donors).
Overall, twelve skin samples were used. The testing protocol was identical to that
described in Example 4.
Figure 11 shows that cumulated delivery of testosterone through the skin after
24 hours was 1.225µg/cm² with 1% testosterone gel containing 15%wt propylene glycol
versus 0.743 µg/cm² with 1% testosterone containing 20%wt propylene glycol.
Figure 11 most surprisingly shows that opposite thereto, increasing the
concentration of propylene glycol from 15% wt to 20%, respectively, in the 2%wt
testosterone gel led to an unexpected increase of cumulated delivery of testosterone
through the skin after 24 hours: 1.877 µg/cm² versus 2.371 µg/cm², respectively.
B. IN VIVO EXAMPLES
Example 6: In vivo study of testosterone transdermal formulations in
human males
The testosterone gel formulations produced essentially as described in Example
1, were assessed in vivo as follows. The objectives of the in vivo study were to
determine the relative bioavailability, pharmacokinetic profile and assess the safety and
tolerability of transdermal testosterone gel formulations comprising 1% and 2%
testosterone after single and repeated transdermal administrations to healthy men for 7
days of repeated dosing, as compared with TESTOGEL/ANDROGEL® (containing 1%
testosterone gel for transdermal application, manufactured by Laboratories Besins
International).
Ten (10) healthy male subjects were included in the study, 18-45 years of age.
The study included three randomized treatment periods of each 7 days with a 6-9 day
wash-out period in between, as follows:
- Treatment period A: a subject was administered the 1%wt testosterone gel,
- Treatment period B: the same subject was administered the 2%wt
testosterone gel,
- Treatment period C: the same subject was administered with
ANDROGEL®.
Before inclusion into the study, all subjects underwent general physical
examination, including vital signs, 12-lead ECG, and laboratory assessment including
haematology, clinical chemistry (including PSA), haemostasis and urinalysis. To ensure
that the subjects had low levels <1 ng/mL of endogenous testosterone, subjects received
two doses (3.75 mg) of the GnRH agonist DECAPEPTYL N®, in order to suppress the
endogenous production of testosterone. DECAPEPTYL N® (triptorelin 3.75 mg 1
month depot) was provided as a pre-filled syringe with powder and 1 mL of solvent for
suspension. DECAPEPTYL N® was suspended in 1 mL, giving a concentration of 3.75
mg/mL of which 1 mL was injected in the gluteal muscle. The first dose of
DECAPEPTYL N® was administered on Day -21 and the second dose was
administered 28 days later, i.e. on Day 8 of the first treatment period.
The subjects came for residential stays on Days 1 and 7 in each treatment period.
In addition, the subjects came for ambulatory visits on Days 3 to 6. Between treatment
periods there was a wash-out period of 6-9 days. A follow-up visit was conducted 14
days after the last treatment period to ensure that the level of testosterone has returned
to normal. LH was measured on Day -1 and on Days 1 to 8 in each treatment period in
order to detect if any subject escaped down regulation during treatment.
A dose of 5 g of the testosterone gel 1% , a dose of 2.5 g of testosterone gel 2%
or 5 g of ANDROGEL®, were administered in each treatment period, to the same 1000
cm² area of the abdomen once daily for 7 days during each treatment period. The dose
was applied to the area until the gel was completely absorbed. The application site was
allowed to dry before covered with clothes.
Blood/serum samples were collected as follows in each treatment period on:
Day 1: Pre-dose (0) (i.e. prior to the administration of the first dose) and thereafter on 2,
4, 6, 8, 12, and 16 hours after the first dose.
Days 2 – 6: Pre-dose only
Day 7: Pre-dose, 2, 4, 6, 8, 12, 16, 24, and 48 (day 8) hours after the last administration.
The testosterone concentration in the serum samples was quantified using
known methods, using supported liquid extraction by quantification using ultra
performance liquid chromatography with mass spectrometric detection (UPLC-
MS/MS).
Pharmacokinetic (PK) parameters were estimated using non-compartmental
analysis. PK parameters were calculated based on measurements from Day 1 to Day 2,
and from Day 7 to Day 8. PK parameters AUC and C were compared across
τ max
treatment groups using an ANOVA model for the log-transformed values. The ratio of
the PK parameters was estimated along with 90% confidence limits. Analysis of
testosterone and radio-labelled H -Testosterone was carried out using a UPLC-MS/MS
system.
Table 7 below presents the mean and standard deviation (SD) in vivo
testosterone concentration results of 1%wt and 2%wt testosterone gel formulations and
of ANDROGEL. Table 8 shows the C and AUC results for the two tested
max τ
formulations and ANDROGEL.
Table 7 – In vivo testosterone concentrations (ng/dL) for 1%wt and 2%wt
formulations and ANDROGEL®
Day of Time (h) Testosterone Gel Testosterone Gel ANDROGEL ®
treatment 1% 2%
Mean SD Mean SD Mean SD
0 (Pre-dose) 0h 42.66 40.13 34.04 27.54 32.41 24.22
0 2h 127.46 120.87 101.43 41.59 57.81 39.24
0 4h 527.20 338.79 313.10 112.32 86.18 40.21
0 6h 553.70 231.06 281.40 71.24 107.74 48.55
0 8h 391.70 175.98 199.20 34.05 104.67 61.09
0 12h 271.20 83.86 169.80 20.84 147.58 96.93
0 16h 213.00 48.65 152.90 27.85 139.78 46.63
Day 1 24h 184.80 54.96 157.70 59.02 155.55 40.47
Day 2 (Pre-dose) 48h 205.20 87.46 126.22 68.30 157.29 84.15
Day 3 (Pre-dose) 72h 168.37 67.96 149.22 81.85 152.80 68.61
Day 4 (Pre-dose) 96h 124.74 62.19 139.03 55.61 178.51 110.18
Day 5 (Pre-dose) 120h 135.00 56.66 162.46 73.82 155.03 73.18
Day 6 (Pre-dose) 144h 160.82 86.87 204.90 83.54 188.89 107.25
Day 6+2h 146 256.80 232.08 222.80 101.40 167.52 87.14
Day 6+4h 148 604.10 312.83 326.30 105.58 195.42 90.57
Day 6+6h 150 565.20 220.35 316.40 81.68 178.08 61.26
Day 6+8h 152 402.00 147.53 242.40 76.59 184.28 77.23
Day 6+12h 156 320.60 95.44 225.50 64.60 190.76 74.35
Day 6+16h 160 235.70 54.44 219.60 85.93 165.68 54.23
Day 7 168 199.90 60.35 189.20 61.53 207.00 58.75
Day 8 192 92.24 42.48 133.61 70.04 103.68 59.10
Table 8 - PK values of final dose (s.s)
AUC SD RSD C SD RSD
τ max
(ng*hr/dL) (ng/dL)
6691.38 2452.2 36.6% 602.3 284.7 47.3%
Testosterone Gel
4822.54 1757.4 36.4% 316.9 98.1 31.0%
Testosterone Gel
ANDROGEL® 3631.05 1409.9 38.8% 231.1 93.5 40.4%
The data presented show that the 2% formulation provides more sustained and
controlled plasma levels over all time points with significant less C values. In
addition the 2% testosterone gel provides less relative variability judged by the SD
obtained.
Figure 12 shows the daily plasma profile at steady state in the down-regulated
males for the two testosterone gel formulations tested after the last administration, i.e. at
168 hours until 192 hours (see Table 7) with each formulation. Testosterone plasma
levels following daily administration of 2.5g of testosterone gel 2% (50 mg testosterone
daily) for seven days was shown to be more controlled with less fluctuations than the
testosterone plasma levels following daily administration of 5g of testosterone gel 1%
(50 mg testosterone daily).
Additionally, peak value (C ) was found to be lower for the 2%wt testosterone
gel than for the 1%wt testosterone gel. The in vivo variability of C was less
pronounced for the 2%wt testosterone gel than for the 1%wt testosterone gel (RSD of
31.0%, versus 47.3%: see Table 8), whereas the in vivo variability of AUC was similar
for both testosterone gel strengths (about 36%).
Thus, administration of 2%wt testosterone gel resulted in a more regulated
testosterone plasma level with less variations compared to administration of 1%wt
testosterone gel. Thus, 2%wt testosterone gel provided a more steady therapeutic effect
resulting in less side effects than 1%wt testosterone gel.
Example 7
In order to achieve equivalent plasma levels as achieved with a daily dose of 10
grams 1% ANDROGEL®, about 5.4 grams of the 1% testosterone gel were needed or
about 3.7 grams of 2%wt testosterone gel of the invention were needed.
Figure 13 demonstrates the difference in the volume amount of transdermal
testosterone formulation to be applied when using 1% testosterone gel compared to
2%wt testosterone gel.
The above data show that for a given daily dose of testosterone (e.g. 50 mg),
daily administration of the 2%wt testosterone gel provides superior advantages over the
use of the 1%wt testosterone gel, as the former leads to smoother plasma profiles
together with a lower formulation dose and reduced dosing frequency, hence to an
improved activity/safety profile for the patient in need thereof.
The formulations of the invention thus demonstrate an advantageous once daily
administration volume. Such advantageous administration volume results in a shortened
administration time, in a decrease in the amount of unabsorbed testosterone left on the
skin of a subject, in a decreased exposure of the surroundings to the testosterone, and to
a decreased exposure of the testosterone to degradation processes. Accordingly,
formulations of the invention were shown to deliver therapeutic amounts of testosterone
by a convenient and simplified dosing regimen.
Example 8: A phase 2 open-label, sequential dose escalation study to
evaluate the efficacy, pharmacokinetics and safety of three volumes of transdermal
testosterone gel formulation comprising 2% testosterone in hypogonadal males
The primary objectives of the study were to determine the pharmacokinetics of
total testosterone after 10 days of treatment with each of three volumes - 1.25, 2.50 and
3.75 mL - of transdermal testosterone gel formulation comprising 2% testosterone
(produced essentially as described in Example 1) in hypogonadal males and to
determine if the treatments restore the testosterone to the normal male physiologic range
(which is about 298 to 1,043 ng/dL for total testosterone).
The three volumes - 1.25, 2.50 and 3.75 mL- of transdermal testosterone gel
formulation comprising 2% testosterone are respectively equivalent to 23, 46 and 70 mg
of testosterone and to 1.15, 2.3 and 3.45 grams of gel.
The secondary pharmacokinetic objectives of the study were to determine the
kinetics of a single dose of 2.50 mL of transdermal testosterone gel formulation
comprising 2% testosterone (produced essentially as described in Example 1) applied to
three different locations: thigh, abdomen, and shoulder.
In the first part of the study, subjects received sequential single applications of
2.50 mL gel applied to the inner thigh, abdomen, and shoulder/upper arm. Plasma
samples were collected at intervals (pre-dose and at 2, 4, 6, 8, 10, and 24 hr post-dose)
up to 24 hr for pharmacokinetic analysis. Following the first two single doses, there
were 5- to 7-day washout periods, but only a 24-hr period after the third dose before the
start of the second part of the study.
In the second part of the study, multiple daily doses of 1.25 mL were applied to
the shoulder/upper arm for 10 days, followed by 2.50 mL for 10 days, followed by 3.75
mL for 10 days, with no washout between dose levels. Samples for pharmacokinetic
analysis were collected on the 10 day of each dose level. For each of the
pharmacokinetic profiles, blood samples were collected pre-dose and at 2, 4, 6, 8, 10,
and 24 hr post-dose.
Twenty subjects entered and completed both parts of the study.
Four analytes were measured: total testosterone, free testosterone,
Dihydrotestosterone (DHT), and sex hormone binding globulin (SHBG). For total and
free testosterone and DHT, C , T , C , T , AUC , and C were calculated
max max min min 0-24 ave
using non-compartmental pharmacokinetic models. For SHBG, C was calculated.
Total testosterone in serum was determined by high pressure liquid
chromatography with tandem mass spectrometry detection (LC/MS/MS). The percent
of free testosterone was determined by equilibrium dialysis, and the concentration of
free testosterone in the serum was calculated using the concentration of total
testosterone and the percentage of free testosterone. The serum concentrations of the
testosterone metabolite, DHT, were determined by LC/MS/MS. The concentrations of
SHBG were determined by an immunoradiometric assay (IRMA).
The results for the single applications of 2.50 mL to the thigh, abdomen, and
shoulder are shown in Table 9.
Table 9
Pharmacokinetic Parameters for Single Applications
C T (hr) C T (hr) AUC C
max max min min 0-24 ave
Mean ± SD Median Mean ± SD Median Mean ± SD Mean ± SD
Total Testosterone (units of ng/dL for C , C , and C , units of ng•hr/dL for AUC )
max min ave 0-24
Thigh 519 ± 171 24.0 304 ± 81 5.0 9,473 ± 2,306 395 ± 96
Abdomen 451 ± 157 9.0 268 ± 61 0 8,917 ± 2,925 372 ± 122
Shoulder 926 ± 737 11.0 289 ± 71 0 13,368 ± 7,162 557 ± 298
Free Testosterone (units of pg/mL for C , C , and C , units of pg•hr/mL for AUC )
max min ave 0-24
Thigh 101 ± 35 24.0 51.0 ± 20.4 3.0 1,738 ± 534 72.4 ± 22.2
Abdomen 96.4 ± 49.2 8.0 43.5 ± 14.4 5.0 1,639 ± 775 68.3 ± 32.3
Shoulder 182 ± 137 7.0 49.6 ± 18.7 1.0 2,863 ± 1,734 119 ± 72
DHT (units of ng/dL for C , C , and C , units of ng•hr/dL for AUC )
max min ave 0-24
Thigh 61.5 ± 28.2 10.0 22.9 ± 8.1 0 1,173 ± 589 48.9 ± 24.5
Abdomen 45.9 ± 19.1 8.0 22.8 ± 9.3 0 884 ± 407 36.9 ± 17.0
Shoulder 76.3 ± 53.8 9.0 22.0 ± 7.9 0 1,262 ± 758 52.6 ± 31.6
SHBG (units of nM for C )
Thigh - - - - - 26.3 ± 9.7
Abdomen - - - - - 24.0 ± 8.5
Shoulder - - - - - 25.3 ± 9.2
The results for multiple applications for 10 days of 1.25, 2.50, and 3.75 mL gel
to the shoulder are shown in Table 10.
Table 10
Pharmacokinetic Parameters for Multiple Applications
C T (hr) C T (hr) AUC C
max max min min 0-24 ave
Mean ± SD Median Mean ± SD Median Mean ± SD Mean ± SD
Total Testosterone (units of ng/dL for C , C , and C , units of ng•hr/dL for AUC )
max min ave 0-24
1.25 mL 586 ± 290 6.0 261 ± 83 8.0 9,229 ± 2,946 385 ± 123
2.50 mL 907 ± 784 5.0 289 ± 111 5.0 12,113 ± 6,309 505 ± 263
3.75 mL 1,258 ± 774 6.0 381 ± 174 7.0 17,633 ± 9,256 735 ± 386
Free Testosterone (units of pg/mL for C , C , and C , units of pg•hr/mL for AUC )
max min ave 0-24
1.25 mL 134 ± 90 6.0 49.4 ± 20.2 7.0 1,766 ± 781 73.6 ± 32.5
2.50 mL 203 70.8 2,342 97.6
3.75 mL 382 ± 342 6.0 86.4 ± 57.5 5.0 4,686 ± 3,575 195 ± 149
DHT (units of ng/dL for C , C , and C , units of ng•hr/dL for AUC )
max min ave 0-24
1.25 mL 64.4 ± 32.2 6.0 34.9 ± 15.2 9.0 1,063 ± 497 44.3 ± 19.9
2.50 mL 93.3 ± 51.9 4.0 41.7 ± 18.1 12.0 1,458 ± 727 60.7 ± 30.3
3.75 mL 120 ± 60 6.0 54.6 ± 24.6 6.0 1,974 ± 890 82.2 ± 37.1
SHBG (units of nM for C )
1.25 mL - - - - - 22.9 ± 8.4
2.50 mL - - - - - 21.8 ± 7.8
3.75 mL - - - - - 23.6 ± 8.9
Note: Due to multiple missing concentration values, individual parameters for free testosterone could not
be calculated for 2.50 mL multiple applications. The values in the table for 2.50 mL were calculated
using mean concentrations.
Conclusions:
Total Testosterone: For the single applications, the results for thigh and
abdomen were similar. For the shoulder, the mean, median, and maximum values for
C , AUC , and C were higher than the corresponding values for the thigh or
max 0-24 ave
abdomen. For multiple applications to the shoulder, mean, median, minimum and
maximum values for C , C , AUC , and C increased with increasing dose. The
max min 0-24 ave
effects of application site and dose on C were statistically significant (p < 0.05).
Free Testosterone: For single applications, the results for free testosterone for
the thigh and abdomen were similar. For the shoulder, the mean, median, and
maximum values for C , AUC , and C were higher than the corresponding values
max 0-24 ave
for the thigh or abdomen. For multiple applications, the mean, median, and maximum
values for C , C , AUC , and C increased with increasing dose. Some
max min 0-24 ave
individual subjects showed distinct increases with dose, but other subjects did not show
dose-related increases. The effects of application site and dose on C were statistically
significant (p < 0.05).
DHT: For single applications, C , AUC , and C , were similar for the
max 0-24 ave
thigh and shoulder, with apparently lower values for the abdomen. However, there was
no statistically significant effect (p = 0.218) on C or AUC . C was nearly
ave 0-24 min
identical for all three sites. The plasma concentration time profiles showed evidence of
absorption and metabolism of testosterone. The mean minimum concentrations of DHT
for single applications were the baseline pre-dose concentrations and the maximum
concentrations were at a distinctly later time. For the multiple applications, the mean,
median, and maximum values for C , C , AUC , and C , increased with
max min 0-24 ave
increasing dose. The increases in C with increasing gel volume were statistically
significant (p < 0.05).
SHBG: For both single and multiple applications, the values of C were
similar for all sites and doses. Neither application site nor gel volume had a statistically
significant effect on C (p = 0.738 and 0.784, respectively).
Overall: The mean concentrations and pharmacokinetic parameters showed
evidence of dose-dependent absorption of testosterone with subsequent metabolism to
DHT.
Claims (31)
1. A transdermal or transmucosal formulation comprising: - 2% wt of testosterone, - C to C alkanol, 5 - polyalcohol, and - a monoalkyl ether of diethylene glycol permeation enhancer, wherein said formulation comprises fatty alcohols, fatty acids, and fatty esters having a branched or linear acid moiety having 8 or more carbon atoms or having a branched or linear alcohol moiety having 8 or more carbon atoms in a total amount of 10 less than 0.1% wt.
2. The formulation of claim 1, further comprising at least one of: - gelling agent, - neutralizing agent, 15 - chelating agent and - solvent or any combinations thereof.
3. The formulation of claim 1 or 2, wherein the alkanol is present in an amount 20 between 5 – 50%wt, the polyalcohol is present in an amount between about 1 – 30%wt, the permeation enhancer is present in an amount of between 0.2 – 25%wt, the gelling agent is present in an amount between 0.05 - 4%wt, the neutralizing agent is present in an amount between 0.05-1 %wt, and the chelating agent is present in an amount between 0.001-5.0%wt.
4. The formulation of claim 1 or 2, wherein the alkanol is selected from one or more of the group consisting of ethanol, isopropanol and n-propanol .
5. The formulation of claim 4, wherein the alkanol is ethanol.
6. The formulation of claim 5, wherein ethanol is present in an amount of 44.0%wt.
7. The formulation of claims 1 or 2, wherein the polyalcohol is propylene glycol.
8. The formulation of claim 7, wherein the polyalcohol is propylene glycol, present in an amount of 20.0%wt.
9. The formulation of claims 1 or 2, wherein one or both of diethylene glycol monoethyl ether and diethylene glycol monomethyl ether are present.
10. The formulation of claims 1 or 2, wherein diethylene glycol monoethyl ether is 10 present in an amount of 5.0%wt.
11. The formulation of claim 2, wherein the gelling agent is carbomer.
12. The formulation of claim 11, wherein the carbomer is present in an amount of 15 1.20%wt.
13. The formulation of claim 12, wherein the gelling agent is carbomer C980NF.
14. The formulation of claim 2, wherein the neutralizing agent is triethanolamine.
15. The formulation of claim 14, wherein triethanolamine is present in an amount of 0.35%wt.
16. The formulation of claim 2, wherein the chelating agent is edetate disodium.
17. The formulation of claim 16, wherein the edetate disodium is present in an amount of 0.06%wt.
18. The formulation of claim 2, wherein the solvent is water.
19. The formulation of claim 1 comprising either: (1) 2% wt of testosterone, 44.0%wt of ethanol, 20.0%wt of propylene glycol, and 5.0%wt of diethylene glycol monoethyl ether, or (2) 2% wt of testosterone, 44.0%wt of ethanol, 20.0%wt of propylene glycol, 5.0%wt of diethylene glycol monoethyl ether, 1.20%wt of carbomer, 0.35%wt of triethanolamine, 0.06%wt of edetate disodium and water, 5 or (3) consisting of 2% wt of testosterone, 44.0%wt of ethanol, 20.0%wt of propylene glycol, 5.0%wt of diethylene glycol monoethyl ether, 1.20%wt of carbomer, 0.35%wt of triethanolamine, 0.06%wt of edetate disodium and water.
20. The formulation of any one of claims 1 to 19, wherein said formulation is in the 10 form of a gel, lotion, cream, spray, aerosol, ointment, emulsion, suspension, liposomal system, lacquer, patch, bandage, buccal tablet, sublingual tablet, suppository, vaginal dosage form or occlusive dressing.
21. A formulation of claim 20, wherein said formulation is in the form of a gel.
22. The formulation of any one of claims 1 to 21, wherein said formulation is adapted for transdermal or transmucosal administration according to a schedule having a periodicity selected from once to five times daily dosing, once-weekly dosing or bi- weekly dosing.
23. A formulation of claim 22, wherein said formulation is adapted for a once daily transdermal or transmucosal administration.
24. A formulation of claim 23, wherein said formulation is adapted for a once daily 25 transdermal or transmucosal administration to the abdomen of a mammal in need thereof.
25. A formulation of claim 23, wherein said formulation is adapted for a once daily transdermal or transmucosal administration to the upper arm of a mammal in need 30 thereof.
26. The use of a formulation according to any one of claims 1 to 25 in the manufacture of a medicament for transdermal administration to a skin or mucosal membrane of a mammal, preferably a male mammal.
27. The use of a formulation according to any one of claims 1 to 25 in the manufacture of a medicament for treating a disease or disorder of a mammal associated with reduced endogenous testosterone production wherein said mammal is a male 5 mammal.
28. The use of a formulation according to any one of claims 1 to 25 in the manufacture of a medicament for treating hypogonadism. 10
29. The formulation according to any one of claims 1 to 25, wherein said formulation is for administration in combination with another treatment.
30. A kit comprising at least one container comprising a formulation according to any one of claims 1 to 25, and instructions for use thereof,
31. A kit according to claim 30, wherein said container is adapted for dispensing a predetermined measured amount of said formulation.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161436207P | 2011-01-26 | 2011-01-26 | |
EP11152210 | 2011-01-26 | ||
US61/436,207 | 2011-01-26 | ||
EP11152210.8 | 2011-01-26 | ||
PCT/EP2012/050695 WO2012101016A1 (en) | 2011-01-26 | 2012-01-18 | Testosterone formulations |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ613029A NZ613029A (en) | 2014-03-28 |
NZ613029B true NZ613029B (en) | 2014-07-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8895053B2 (en) | Testosterone formulations | |
CA2515426C (en) | Uses and formulations for transdermal or transmucosal application of active agents | |
US8338400B2 (en) | Methods and apparatus for transdermal or transmucosal application of testosterone | |
US20110195114A1 (en) | Transdermal delivery systems for active agents | |
KR20070099532A (en) | Testosterone gels comprising propylene glycol as penetration enhancer | |
EP2303281A1 (en) | Transdermal pharmaceutical compositions comprising danazol | |
NZ613029B (en) | Testosterone formulations |